Obesity

Obesity-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
May 25, 2017 - N°20170145000

The present invention relates to canagliflozin monohydrate and its crystalline forms. Compared to the prior art, canagliflozin monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability. The present invention also relates to preparation methods of canagliflozin monohydrate and its crystalline forms, ...
NEW Application of gpr45 gene
May 25, 2017 - N°20170143850

The present invention relates to the field of biotechnology, in particular to application of a gpr45 gene. The present invention discloses, for the first time, a correlation between gpr45 and obesity and also discloses that obesity may be caused if the gpr45 gene is knocked out or the expression of the gpr45 gene is reduced. Moreover, an obese mouse model ...
NEW Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
May 25, 2017 - N°20170143779

The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an aav virion comprising an aav vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are aav vectors and aav ...
NEW Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
May 25, 2017 - N°20170143666

Provided are compositions comprising compounds or precursors to compounds which may be used for a. Variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ...
NEW Devices and methods for endolumenal treatment of obesity
May 25, 2017 - N°20170143524

Devices and methods for forming and securing tissue folds and elongated invaginations in stomach tissue are used as a treatment for obesity. In a first embodiment, a plurality of tissue folds is formed in the fundus region of the stomach. In methods for surgically altering stomach tissue to change gastric emptying, plications are formed in the stomach to speed up ...
NEW Stomach-spanning gastric implants
May 25, 2017 - N°20170143523

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive implants do not autonomously change shape, but instead react within the stomach to induce satiety. The implants may take up volume within the stomach, thus reducing the digestive capacity. Additionally, the implants may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Long-acting single-chain insulin analogues
Case Western Reserve University
May 18, 2017 - N°20170137488

A single-chain insulin analogue containing a basic side chain at position a8 (arginine, histidine, lysine, or ornithine), a basic side chain at position b29 (arginine, histidine, lysine, or ornithine), and a foreshortened c-domain of length 6-11 residues is provided. Residues c1 and c2 of the c-domain have a net negative charge of −1 or −2; c3 is chosen from a ...
Peptide yy (pyy) analogues
Imperial Innovations Limited
May 18, 2017 - N°20170137486

Analogues of peptide yy (pyy), which are useful in treating disorders such as diabetes and obesity and also for inducing cosmetic weight loss, related compositions, formulations, uses and methods.
Kv1.3 potassium channel antagonists
Conogenetix Biosciences Gmbh
May 18, 2017 - N°20170137470

The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel kv1. 3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection.
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
The General Hospital Corporation
May 18, 2017 - N°20170136095

Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, lvkgramide, derived from the c-terminus of glucagon-like peptide 1 (glp-1).
Pharmaceutical compositions of berberine with epa and dha, and methods thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
May 18, 2017 - N°20170135995

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, ...
Method for suppressing glucagon secretion of an sglt2 inhibitor
Astrazeneca Ab
May 18, 2017 - N°20170135981

Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (...
Implantable electroacupuncture system and method for treating dyslipidemia and obesity
Valencia Technologies Corporation
May 18, 2017 - N°20170135898

An exemplary method of treating obesity or dyslipidemia of a patient includes 1) generating, by an electroacupuncture device implanted beneath a skin surface of the patient, stimulation sessions at a duty cycle that is less than 0. 05, and 2) applying, by the electroacupuncture device in accordance with the duty cycle, the stimulation sessions to at least one of a saphenous nerve and a ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Integrated physical activity level (i-pal) measurement and tracking in adolescents and older teenagers
The Feinstein Institute For Medical Research
May 04, 2017 - N°20170124288

Described are systems that include at least one sub-system to track, measure, monitor and reward adolescents and young adults for performing daily physical activities, which include before-school, in-school, after-school, sports and activities of daily living. The system offers adolescents the opportunity to track their integrated physical activity level (i-pal) scores over their adolescent years. Also described are systems that include ...
Ppar modulators
FundaÇao Universidade De BrasÍlia
May 04, 2017 - N°20170121268

The present application relates to amorfrutin analogs and uses as ppar modulators for the treatment of metabolic syndrome, obesity, hyperlipidemia, elevated fasting blood glucose, elevated blood pressure, low hdl cholesterol, type 2 diabetes, cardiovascular disease, a neurodegenerative disease, malaria or irritable bowel syndrome.
Methods for treating obesity and/or metabolic syndrome
Mesoblast, Inc.
May 04, 2017 - N°20170119822

The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
Tetrazolones as inhibitors of fatty acid synthase
Mesoblast, Inc.
May 04, 2017 - N°20170119734

Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
Combination therapy for effecting weight loss and treating obesity
Mesoblast, Inc.
May 04, 2017 - N°20170119730

The combination methods of the present invention also are effective against symptoms associated with syndrome x. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods ...
The Hershey Company
May 04, 2017 - N°20170119729

The invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase a2 (pla2), and cox-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and ...
Methods, devices, and systems for obesity treatment
Fulfillium, Inc.
May 04, 2017 - N°20170119566

In one aspect, a gastric balloon structure includes multiple isolated non-concentric inflatable chambers and a valve system for introducing fluid into each chamber, where the structure assumes, upon inflating, a curved shape conforming to a natural three-dimensional kidney shape of the gastric cavity.
Double-acylated glp-1 compounds
Novo Nordisk A/s
April 27, 2017 - N°20170114116

The invention relates to a derivative of a glp-1 peptide, which peptide comprises a first lys residue at a position corresponding to position 36 of glp-1(7-37) (seq id no:1), a second lys residue at a position corresponding to position 37 of glp-1(7-37) (seq id no: 1), and a maximum of seven amino acid changes as compared to glp-1(7-37) (seq id ...